Advertisement

Current Urology Reports

, 19:76 | Cite as

Role of Angio-Embolization for Renal Cell Carcinoma

  • Andrew J. Gunn
  • Anand R. Patel
  • Soroush Rais-Bahrami
New Imaging Techniques (S Rais-Bahrami and K Porter, Section Editors)
Part of the following topical collections:
  1. Topical Collection on New Imaging Techniques

Abstract

Purpose of Review

To provide the technical aspects of, clinical indications for, status of the current literature on, and emerging concepts in trans-arterial embolization (TAE) for renal cell carcinoma.

Recent Findings

TAE has been evaluated in several retrospective series as a neoadjuvant therapy prior to surgical resection of RCC to reduce tumor vascularity and minimize intra-operative blood loss. TAE has also been examined retrospectively as a neoadjuvant therapy prior to the percutaneous ablation of RCC to reduce blood loss and procedural complications. TAE can potentially palliate symptoms of RCC such as pain and hematuria. Trans-arterial chemoembolization and trans-arterial radioembolization are emerging concepts for RCC.

Summary

Although there have been no prospective, randomized trials demonstrating improved clinical or oncologic outcomes from TAE for patients with RCC, several retrospective studies have shown encouraging results.

Keywords

Renal cell carcinoma Embolization Ablation Nephrectomy Palliation 

Notes

Compliance with Ethical Standards

Conflict of Interest

Andrew J. Gunn is a paid speaker for BTG.

Anand R. Patel declares no potential conflicts of interest.

Soroush Rais-Bahrami is a section editor for Current Urology Reports.

Human and Animal Rights

All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Gunn AJ, Gervais DA. Percutaneous ablation of the small renal mass: techniques and outcomes. Semin Interv Radiol. 2014;31(1):33–41.CrossRefGoogle Scholar
  3. 3.
    Hinshaw JL, Lubner MG, Ziemlewicz TJ, Lee FT, Brace CL. Percutaneous tumor ablation tools: microwave, radiofrequency, or cryoablation – what should you use and why? Radiographics. 2014;34(5):1344–62.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Higgins LJ, Hong K. Renal ablation techniques: state of the art. AJR Am J Roentgenol. 2015;205(4):735–41.CrossRefPubMedGoogle Scholar
  5. 5.
    Ginzburg S, Tomaszewski JJ, Kutikov A. Focal ablation therapy for renal cancer in the era of active surveillance and minimally invasive partial nephrectomy. Nat Rev Urol. 2017;14(11):669–82.CrossRefPubMedGoogle Scholar
  6. 6.
    •• Talenfeld AD, Gennarelli RL, Elkin EB, Atoria CL, Durack JC, Huang WC, et al. Percutaneous ablation versus partial nephrectomy and radical nephrectomy for T1a renal cancer: a population-based analysis. Ann Intern Med. 2018;  https://doi.org/10.7326/M17-0585. Large, population-based analysis of over 4300 patients over a 52-month period which demonstrates that percutaneous ablation has similar oncologic outcomes to radical nephrectomy in T1a disease with less detrimental effects on renal function and fewer procedure-related complications.
  7. 7.
    Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol. 2001;166(5):1611–23.CrossRefPubMedGoogle Scholar
  8. 8.
    Jayson M, Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. Urology. 1998;51(2):203–5.CrossRefPubMedGoogle Scholar
  9. 9.
    Lin SP, Bierhals AJ, Lewis JS Jr. Best cases from the AFIP: metastatic renal cell carcinoma. Radiographics. 2007;27(5):1801–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Ramaswamy RS, Darcy MD. Arterial embolization for the treatment of renal masses and traumatic renal injuries. Tech Vasc Interv Radiol. 2016;19(3):203–10.CrossRefPubMedGoogle Scholar
  11. 11.
    Goldstein HM, Medellin H, Beydoun MT, Wallace S, Ben-Menachem Y, Bracken RB, et al. Transcatheter embolization of renal cell carcinoma. Am J Roentgenol Radium Therapy, Nucl Med. 1975;123(3):557–62.CrossRefGoogle Scholar
  12. 12.
    Patel IJ, Davidson JC, Nikolic B, Salazar GM, Schwartzberg MS, Walker TG, et al. Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. J Vasc Interv Radiol. 2012;23(6):727–36.CrossRefPubMedGoogle Scholar
  13. 13.
    Sauk S, Zuckerman DA. Renal artery embolization. Semin Interv Radiol. 2011;28(4):396–406.CrossRefGoogle Scholar
  14. 14.
    Gunn AJ, Mullenbach BJ, Poundstone MM, Gordetsky JB, Underwood ES, Rais-Bahrami S. Trans-arterial embolization of renal cell carcinoma prior to percutaneous ablation: technical aspects, institutional experience, and brief review of the literature. Curr Urol. 2018; In pressGoogle Scholar
  15. 15.
    Yamakado K, Nakatsuka A, Kobayashi S, Akeboshi M, Takaki H, Kariya Z, et al. Radiofrequency ablation combined with renal arterial embolization for the treatment of unresectable renal cell carcinoma larger than 3.5 cm: initial experience. Cardiovasc Intervent Radiol. 2006;29(3):389–94.CrossRefPubMedGoogle Scholar
  16. 16.
    Nakasone Y, Kawanaka K, Ikeda O, Tamura Y, Yamashita Y. Sequential combination treatment (arterial embolization and percutaneous radiofrequency ablation) of inoperable renal cell carcinoma: single-center pilot study. Acta Radiol. 2012;53(4):410–4.CrossRefPubMedGoogle Scholar
  17. 17.
    Mondshine RT, Owen S, Mondschein JI, Cizman B, Stavropoulos SW, Clark TW. Combination embolization and radiofrequency ablation therapy for renal cell carcinoma in the setting of coexisting arterial disease. J Vasc Interv Radiol. 2008;19(4):616–20.CrossRefPubMedGoogle Scholar
  18. 18.
    • Arima K, Yamakado K, Kinbara H, Nakatsuka A, Takeda K, Sugimura Y. Percutaneous radiofrequency ablation with transarterial embolization is useful for treatment of stage 1 renal cell carcinoma with surgical risk: results at 2-year mean follow up. Int J Urol. 2007;14(7):585–90. Largest retrospective series analyzing the utility of trans-arterial embolization prior to percutaneous ablation in RCC showing technical feasibility and no hemorrhagic complications. CrossRefPubMedGoogle Scholar
  19. 19.
    Tacke J, Mahnken A, Bucker A, Rohde D, Gunther RW. Nephron-sparing percutaneous ablation of a 5 cm renal cell carcinoma by superselective embolization and percutaneous RF-ablation. Rofo. 2001;173(11):980–3.CrossRefPubMedGoogle Scholar
  20. 20.
    Gebauer B, Werk M, Lopez-Hanninen E, Felix R, Althaus P. Radiofrequency ablation in combination with embolization in metachronous recurrent renal cancer in solitary kidney after contralateral tumor nephrectomy. Cardiovasc Intervent Radiol. 2007;30(4):644–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Hall WH, McGahan JP, Link DP, de Vere White RW. Combined embolization and percutaneous ablation of a solid renal tumor. AJR Am J Roentgenol. 2000;174(6):1592–6.CrossRefPubMedGoogle Scholar
  22. 22.
    Winokur RS, Pua BB, Madoff DC. Role of combined embolization and ablation in management of renal masses. Semin Interv Radiol. 2014;31(1):82–5.CrossRefGoogle Scholar
  23. 23.
    Simon SD, Castle EP, Ferrigni RG, Lamm DL, Swanson SK, Novicki DE, et al. Complications of laparoscopic nephrectomy: the Mayo clinic experience. J Urol. 2004;171(4):1447–50.CrossRefPubMedGoogle Scholar
  24. 24.
    Fardoun T, Chaste D, Oger E, Mathieu R, Peyronnet B, Rioux-Leclercq N, et al. Predictive factors of hemorrhagic complications after partial nephrectomy. Eur J Surg Oncol. 2014;40(1):85–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Montag S, Rais-Bahrami S, Seideman CA, Rastinehad AR, Vira MA, Kavoussi LR, et al. Delayed haemorrhage after laparoscopic partial nephrectomy: frequency and angiographic findings. BJU Int. 2011;107(9):1460–6.CrossRefPubMedGoogle Scholar
  26. 26.
    Schwartz MJ, Smith EB, Trost DW, Vaughan ED. Renal artery embolization: clinical indications and experience from over 100 cases. BJU Int. 2007;99(4):881–6.CrossRefPubMedGoogle Scholar
  27. 27.
    Reinhart HA, Ghaleb M, Davis BR. Transarterial embolization of renal tumors improves surgical outcomes: a case series. Int J Surg Case Rep. 2015;15:116–8.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    • Zielinski H, Szmigielski S, Petrovich Z. Comparison of preoperative embolization followed by radical nephrectomy with radical nephrectomy alone for renal cell carcinoma. Am J Clin Oncol. 2000;23(1):6–12. Retrospective analysis of pre-surgical trans-arterial embolization of RCC with a comparison to a control group matched for several clinical factors demonstrated a 5- and 10-year survival benefit for embolization. CrossRefPubMedGoogle Scholar
  29. 29.
    • May M, Brookman-Amissah S, Pflanz S, Roigas J, Hoschke B, Kendel F. Pre-operative renal arterial embolization does not provide survival benefit in patient with radical nephrectomy for renal cell carcinoma. Br J Radiol. 2009;82(981):724–31. Retrospective analysis of pre-surgical embolization of RCC in 227 patients failed to show any clinical benefits to the additional procedure. CrossRefPubMedGoogle Scholar
  30. 30.
    Subramanian VS, Stephenson AJ, Goldfarb DA, Fergany AF, Novick AC, Krishnamurthi V. Utility of preoperative renal artery embolization for management of renal tumors with inferior vena caval thrombi. Urology. 2009;74(1):154–9.CrossRefPubMedGoogle Scholar
  31. 31.
    Schmit CH, Callstrom MR, Boorjian SA, Johnson MP, Atwell TD, Kurup AN, et al. A comparison of bleeding complications in patients undergoing percutaneous renal cryoablation using cryoprobes with and without heat-based track ablation. J Vasc Interv Radiol. 2018;29(6):874–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Kakarala B, Frangakis CE, Rodriguez R, Georgiades CS. Hemorrhagic complications of percutaneous cryoablation for renal tumors: results from a 7-year prospective study. Cardiovasc Intervent Radiol. 2016;39(11):1604–10.CrossRefPubMedGoogle Scholar
  33. 33.
    •• Miller JM, Julien P, Wachsman A, Van Allan RJ, Friedman ML. The role of embolization in reducing complications of cryoablation in renal cell carcinoma. Clin Radiol. 2014;69(10):1045–9. Small retrospective analysis that showed a reduced rate of complications for percutaneous cryoablation in RCC if the tumor was embolized prior to the procedure. CrossRefPubMedGoogle Scholar
  34. 34.
    •• Gunn AJ, Mullenbach BJ, Poundstone MM, Klimkowski S, Gordetsky JB, Underwood ES, et al. Trans-arterial embolization of renal cell carcinoma as an adjunctive therapy prior to cryoablation: a propensity score matching analysis. Diagn Interv Radiol 2018. In press. Retrospective propensity score matching analysis that failed to demonstrate an objective benefit to trans-arterial embolization prior to percutaneous cryoablation in RCC. Google Scholar
  35. 35.
    De Mulder PH, van Herpen CM, Mulders PA. Current treatment of renal cell carcinoma. Ann Oncol. 2004;15(Suppl 4):iv319–28.PubMedGoogle Scholar
  36. 36.
    • Serafin Z, Karolkiewicz M, Strzesniewski P, Lasek W, Bryczkowski M, Wolski Z. Palliative percutaneous kidney embolization with enbucrilate in patients with renal cell carcinoma: safety and symptom control. Med Sci Monit. 2007;13(Suppl 1):98–104. Largest retrospective series assessing the utility of trans-arterial embolization as a palliative approach in RCC showed improvements in both pain and hematuria. PubMedGoogle Scholar
  37. 37.
    Munro NP, Woodhams S, Nawrocki JD, Fletcher MS, Thomas PJ. The role of transarterial embolization in the treatment of renal cell carcinoma. BJU Int. 2003;93(3):240–4.CrossRefGoogle Scholar
  38. 38.
    Maxwell NJ, Saleem Amer N, Rogers E, Kiely D, Sweeney P, Brady AP. Renal artery embolization in the palliative treatment of renal carcinoma. Br J Radiol. 2007;80(950):96–102.CrossRefPubMedGoogle Scholar
  39. 39.
    • Onishi T, Oishi Y, Suzuki Y, Asano K. Prognostic evaluation of transcatheter arterial embolization for unresectable renal cell carcinoma with distant metastasis. BJU Int. 2001;87(4):312–5. Retrospective study comparing the outcomes of trans-arterial therapy to best supportive care in patients with inoperable RCC showed good symptom control in the therapy group with a prolonged survival. CrossRefPubMedGoogle Scholar
  40. 40.
    •• Karalli A, Ghaffarpour R, Axelsson R, Lundell L, Bozoki B, Brismar T, et al. Transarterial chemoembolization of renal cell carcinoma: a prospective controlled trial. J Vasc Interv Radiol. 2017;28(12):1664–72. Small, randomized, controlled study comparing trans-arterial embolization to trans-arterial chemoembolization prior to surgery in RCC. RCCs treated with chemoembolization showed more necrosis on post-procedural imaging than those treated with trans-arterial embolization. CrossRefPubMedGoogle Scholar
  41. 41.
    •• Clark W, Aslan P, Patel M, Vass J, Cade D, de Silva S, et al. The RESIRT study: feasibility and dosimetry considerations of selective internal radiation therapy (SIRT) using yttrium-90 (Y-90) resin microspheres in patients with primary renal cell carcinoma (RCC). J Vasc Interv Radiol. 2017;28(2 Suppl):S164. Phase I clinical study demonstrating the safety of radioembolization in patients with RCC. CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Andrew J. Gunn
    • 1
  • Anand R. Patel
    • 1
  • Soroush Rais-Bahrami
    • 2
  1. 1.Division of Vascular and Interventional Radiology, Department of RadiologyUniversity of Alabama at BirminghamBirminghamUSA
  2. 2.Department of UrologyUniversity of Alabama at BirminghamBirminghamUSA

Personalised recommendations